On November 23, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of its Interim Report for the period January – September 2021 (Press release, Allarity Therapeutics, NOV 23, 2021, View Source [SID1234595982]). The report is available as an attached document and on the company’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Steve Carchedi, CEO of Allarity Therapeutics, commented on the company’s accomplishments during the period, stating, "It continues to be an exciting time for Allarity and the third quarter of 2021 was no exception. We are now close to a pivotal event in the company’s history: Becoming a US-based company listed on Nasdaq in the US. In parallel to preparing for this pivotal event, we achieved several significant milestones during Q3, including the agreement on irofulven with Lantern Pharma and receiving an acceptance & review notification from the FDA for our pre-market approval (PMA) application for the Dovitinib-DRP companion diagnostic. In line with this progress, in September, we announced our agreement with Lonza Group for the manufacturing of dovitinib. Regarding IXEMPRA and stenoparib, our focus has been on expanding our active clinical trial sites for both programs. Based on this level of overall progress, I remain very optimistic about what Allarity can accomplish once our transformation to becoming a US NASDAQ-listed company is complete."
Summary of the Interim Report for Q3 2021
Consolidated group revenue amounted to 0 MDKK (0 MDKK).
Consolidated group loss before depreciation amounted to -20.3 MDKK (-11.8 MDKK).
Consolidated group loss before net financials amounted to -20.4 MDKK (-12.0 MDKK).
Consolidated net result amounted to -20.6 MDKK (-8.5 MDKK).
Consolidated earnings per share (EPS) amounted to -0.05 DKK (-0.05 DKK).
2020 numbers in brackets.
Highlights during Q3 2021
July
On July 5, Allarity Therapeutics received acceptance & review notification from the U.S. FDA for the Company’s pre-market approval application for the DRP for dovitinib.
On July 7, Allarity Therapeutics issued share units as payment-in-kind for services rendered during the Rights Issue in Q2 2021
On July 25, the company announced that it had entered into an agreement with Lantern Pharma for future clinical development of irofulven.
August
On August 5, the company announced that its oral PARP inhibitor, stenoparib, had demonstrated additional pre-clinical antiviral activity against new variants of Coronavirus.
On August 16, the company published a notice to convene an Extraordinary General Meeting to be held on August 31.
On August 18, the company published an elaboration on the contents of the meeting agenda for the Extraordinary General Meeting announced on August 16.
On August 19, the company announced a new publication date for the publication of the Q2 2021 interim report.
On August 19, the company published the interim report for the period January – June 2021.
On August 23, the company announced that it had filed a Form S-4 Registration Statement with the U.S. Securities & Exchange Commission for Listing of Allarity Therapeutics, Inc. on U.S. Nasdaq.
On August 26, the company announced an extraordinary exercise period for warrants of series ALLR TO 3 set to August 30 – September 13.
On August 31, the company published the minutes of the extraordinary general meeting held announced on August 16.
September
On September 14, the company announced that it had received approximately SEK 16.5 million from subscription to warrants of series ALLR TO 3.
On September 15, the company announced an update to the announcement of the outcome of exercise of the ALLR TO 3 warrants, Allarity had received approximately SEK 23.3 million.
On September 16, the company announced that it would present dovitinib survival data from DRP-screened RCC patients at the ESMO (Free ESMO Whitepaper) 2021 Virtual Congress.
On September 23, the company announced it would collaborate with Lonza Group to Manufacture dovitinib, Allarity’s most advanced clinical therapeutic candidate.
Highlights after the period
November
On November 5, the company announced that the U.S. SEC had issued an order declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement effective.
On November 5, the company published a notice of an extraordinary general meeting to be held on November 22, 2021.
On November 11 the company’s oral PARP inhibitor, stenoparib, had demonstrated pre-clinical antiviral activity against the delta variant of Coronavirus.
On November 22, the Extraordinary General Meeting approved the Reorganization Agreement, initially announced on May 20, 2021.
The report is available on: View Source